Alnylam Pharmaceuticals, Inc. Forecasted to Post FY2018 Earnings of ($5.58) Per Share (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Leerink Swann lowered their FY2018 EPS estimates for shares of Alnylam Pharmaceuticals in a report released on Wednesday, according to Zacks Investment Research. Leerink Swann analyst P. Matteis now anticipates that the biopharmaceutical company will post earnings of ($5.58) per share for the year, down from their previous forecast of ($5.02). Leerink Swann currently has a “Market Perform” rating and a $72.00 target price on the stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. During the same period last year, the company earned ($1.21) earnings per share. The business’s revenue was up 24.8% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. Forecasted to Post FY2018 Earnings of ($5.58) Per Share (NASDAQ:ALNY)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://ledgergazette.com/2017/11/13/leerink-swann-comments-on-alnylam-pharmaceuticals-inc-s-fy2018-earnings-alny.html.

A number of other equities analysts also recently weighed in on ALNY. Stifel Nicolaus reaffirmed a “buy” rating and set a $56.00 price target (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. B. Riley cut their price objective on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Cowen and Company reissued a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday. Chardan Capital reissued a “buy” rating and issued a $124.00 price objective (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Finally, Barclays PLC increased their price objective on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $114.57.

Shares of Alnylam Pharmaceuticals (ALNY) opened at $139.98 on Friday. Alnylam Pharmaceuticals has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a quick ratio of 8.84, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the transaction, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. Insiders have sold 215,797 shares of company stock valued at $25,035,072 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. QS Investors LLC raised its stake in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. The Manufacturers Life Insurance Company increased its stake in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the last quarter. Prudential Financial Inc. bought a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $215,000. CIBC Asset Management Inc bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $221,000. Finally, Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $229,000. Institutional investors own 94.20% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply